Edesa Biotech Inc (EDSA)

0.8400 -0.0110 (-1.29%)
Closed USD Disclaimer
0.8800 +0.0400 (+4.7619%)

Edesa Biotech Inc Company Profile

Equity Type
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on inflammatory and immune-related diseases. The Company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, developing as a treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. ARDS can be caused by viral diseases, including Covid-19, bacterial pneumonia, sepsis, chest injury and other causes. Specifically, EB05 inhibits toll-like receptor 4 (TLR4), an immune signaling protein and an important mediator of inflammation that has been shown to be activated by SARS-COV2 as well as other respiratory infections, such as influenza. In addition to EB05, the Company is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness.
Contact Information
Markham,L3R 5H6 Canada
289 800 9600
Top Executives
Pardeep Nijhawan 51 2019 CEO, Company Secretary & Director
Sean Arthur MacDonald 47 2019 Independent Director
Frank R. Oakes 73 2010 Director
Carlo Sistilli 66 2019 Independent Chairman of the Board
Charles V. Olson 66 2023 Director
Joan Chypyha 56 2023 Director
Patrick Jeffrey Marshall 52 2023 Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.